Please login to the form below

Not currently logged in
Email:
Password:

Icon to set up translational medicine centre in the UK

Expands early phase research presence at new Manchester site

Contract research organisation Icon is expanding its early phase research presence in the UK and setting up a new translational medicine centre.

Based in the Citylabs biomedical centre on the former site of the Manchester Royal Eye Hospital, Icon's Centre of Excellence for Translational Medicine will occupy a 40,000 sq ft site and is due to open before the end of 2013.

At this time Icon will also move the phase I operations of its hospital-based clinical pharmacology unit to Citylabs from its current base on the Manchester Royal Infirmary Campus.

President of Icon Development Solutions Dr Mario Rocci said: “We are pleased to be expanding our early phase development services through the establishment of a Centre of Excellence for Translational Medicine in Citylabs.

“This expansion will enable Icon to increase the capacity of its Clinical Pharmacology Unit in Manchester as well as the scientific services that are essential in providing a world class offering.”

Translational research is a way of conducting scientific research 'from bench to bedside' and also 'from bedside to bench', to ensure the results will be applicable to the relevant patient population 

Along with Icon's Translational Medicine Research Centre, Citylabs be home to a number of other health organisations, including the Central Manchester University Hospitals NHS Foundation Trust, The University of Manchester and commercial research organisations.

Mike Deegan, chief executive of Central Manchester University Hospitals NHS Foundation Trust, said: “This exciting development supports our progress to be the leading hospital for research and patient care in England and Citylabs will strengthen our capability to support the development of new medicines and diagnostics for our patients.

“We are pleased that Icon, who is one of the leaders in early phase trials, is expanding into Citylabs which will help our patients to get early access to leading edge new treatments.”

8th August 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Influencing behaviour change: Looking beyond market research
These strategies will give you the insight you need to influence behaviour change by creating a meaningful pharma customer journey....
Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...

Infographics